Hepatitis C virus nonstructural protein 5A (genotype 1b) (HCV NS5A (genotype 1b))

Hepatitis C virus nonstructural protein 5A (NS5A) is a multifunctional phosphoprotein essential for the HCV life cycle, specifically in genome replication and virion assembly (NIH, 2021). It lacks intrinsic enzymatic activity but functions as a scaffold, interacting with viral proteins like NS5B polymerase and host factors like protein kinase R (PKR) (Tellinghuisen et al., 2005). In genotype 1b, NS5A is notably associated with interferon resistance and the modulation of host immune responses (NIH, 2021). The protein is a primary target for direct-acting antivirals (DAAs) called NS5A inhibitors, which include drugs like daclatasvir, ledipasvir, and velpatasvir (Kanda et al., 2014). These inhibitors bind to Domain I of NS5A, disrupting its dimerization and the formation of the viral replication complex (Gao et al., 2010). While highly potent, NS5A inhibitors are often used in combination with other DAAs to overcome a low genetic barrier to resistance (HCV Guidelines, 2024). Chronic infection with HCV genotype 1b can lead to severe clinical outcomes, including liver cirrhosis and hepatocellular carcinoma (NIH, 2021). Monitoring for resistance-associated substitutions (RASs) is often required to optimize treatment efficacy for patients infected with this genotype (ARUP Consult, 2025).

Other names

NS5ANonstructural protein 5Ap56p58HCV NS5A protein

NS5A inhibitors bind to Domain I of the NS5A protein, which is critical for its dimerization and interaction with the viral replication complex. This binding blocks the protein's ability to support viral RNA replication and the assembly of new virions (Gao et al., 2010; Kanda et al., 2014).